Infliximab vs. Adalimumab for Crohn's disease

被引：3

作者：

Mulani, P. ^{[1
]}

Chao, J. ^{[1
]}

机构：

[1] Abbott Labs, Global Hlth Econ & Outcomes Res, Global Pharmaceut Res & Dev, Abbott Pk, IL 60064 USA

来源：

ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2008年 / 28卷 / 10期

关键词：

D O I：

10.1111/j.1365-2036.2008.03829.x

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：1265 / 1266

页数：2

共 4 条

[1] Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial [J].

Hanauer, SB ;

Feagan, BG ;

Lichtenstein, GR ;

Mayer, LF ;

Schreiber, S ;

Colombel, JF ;

Rachmilewitz, D ;

Wolf, DC ;

Olson, A ;

Bao, WH ;

Rutgeerts, P .

LANCET, 2002, 359 (9317) :1541-1549

[2] Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis [J].

Kaplan, G. G. ;

Hur, C. ;

Korzenik, J. ;

Sands, B. E. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (11-12) :1509-1520

[3] Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease [J].

Rutgeerts, P ;

Feagan, BG ;

Lichtenstein, GR ;

Mayer, LF ;

Schreiber, S ;

Colombel, JF ;

Rachmilewitz, D ;

Wolf, DC ;

Olson, A ;

Bao, WH ;

Hanauer, SB .

GASTROENTEROLOGY, 2004, 126 (02) :402-413

[4] Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial [J].

Sandborn, W. J. ;

Hanauer, S. B. ;

Rutgeerts, P. ;

Fedorak, R. N. ;

Lukas, M. ;

MacIntosh, D. G. ;

Panaccione, R. ;

Wolf, D. ;

Kent, J. D. ;

Bittle, B. ;

Li, J. ;

Pollack, P. F. .

GUT, 2007, 56 (09) :1232-1239

← 1 →